IMPAIRMENT OF ROYALTIES BUYOUT	9 Months Ended
Sep. 30, 2015
Asset Impairment Charges [Abstract]
IMPAIRMENT OF ROYALTIES BUYOUT	NOTE 8– IMPAIRMENT OF ROYALTIES BUYOUT During the nine month period ended September 30, 2015 the Company recorded expenses related to the impairment of our royalties buyout asset amounting to $576,000 due to anticipated lower sales of MGuard Prime in the future resulting from industry preferences for drug eluting stents. The expense is recorded under “Restructuring and impairment expenses” in the consolidated statements of operations.

The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported.

No definition available.

Name:	us-gaap_AssetImpairmentChargesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration